Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar 2;27(10):1667–1674. doi: 10.1200/JCO.2008.19.1635

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — Survival of MET fluorescent in situ hybridization (FISH)+ and MET FISH− according to stage, grade, and epidermal growth factor receptor (EGFR) FISH. (A) In stage I-II disease, 20 patients were MET FISH+ and 233 were MET FISH−. Median survival was not reached in MET FISH− and was 33.0 months in MET FISH+. This difference was statistically significant (P = .032). (B) In stage III-IV disease, MET FISH+ patients (n = 28) had shorter survival (20.8 v 22.8 months) than MET FISH− (n = 150). This difference was not statistically significant (P = .3). (C) In grade 1-2 disease, MET FISH+ (n = 23) had shorter survival (28.1 v 48.8 months) than MET FISH− (n = 250). The difference did not reach the statistical significance (P = .1). (D) In grade 3 disease, MET FISH+ (n = 25) had significantly shorter survival (20.8 v 38.1 months) than MET FISH− (n = 131). The difference was statistically significant (P = .03). (E) EGFR FISH negative/MET FISH− (n = 197) had significantly longer survival (55.9 v 22.6 months; P = .0001) than EGFR FISH−/MET FISH+ (n = 15). (F) Among patients EGFR FISH+, survival was longer in MET FISH− (n = 128) than in the 31 patients MET FISH+ (median survival, 42.6 v 28.9 months) even if the difference was not statistically significant (P = .2).